Evidence map›Paper›PMID 42100023›Full record

ArticleOncology letters2026

Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with vascular invasion: A systematic review and meta-analysis.

Yuhao Su, Yuxin Liang, Deyuan Zhong, Hongtao Yan, Qinyan Yang, Xiaolun Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuhao SuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
Yuxin LiangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
Deyuan ZhongSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
Hongtao YanLiver Transplantation Center and Hepato-Pancreato-Biliary Surgery, Sichuan Cancer Hospital, Affiliated Cancer Hospital, University of Electronic Science and Technology, Chengdu, Sichuan 610042, P.R. China.
Qinyan YangLiver Transplantation Center and Hepato-Pancreato-Biliary Surgery, Sichuan Cancer Hospital, Affiliated Cancer Hospital, University of Electronic Science and Technology, Chengdu, Sichuan 610042, P.R. China.
Xiaolun HuangLiver Transplantation Center and Hepato-Pancreato-Biliary Surgery, Sichuan Cancer Hospital, Affiliated Cancer Hospital, University of Electronic Science and Technology, Chengdu, Sichuan 610042, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in conformal and image-guided external-beam radiotherapy have expanded its application in hepatocellular carcinoma (HCC); however, the benefit of neoadjuvant radiotherapy before resection for HCC with vascular invasion remains uncertain. A systematic review and meta-analysis were conducted comparing neoadjuvant radiotherapy plus hepatectomy vs. hepatectomy alone in resectable HCC with vascular invasion. Databases were searched through August 1, 2024. Primary outcomes were overall survival (OS) and disease-free survival (DFS). A total of four studies (n=362) were included. In the overall pooled analysis, neoadjuvant radiotherapy was not associated with a statistically significant improvement in 1-year OS [risk ratio (RR) 1.62; 95% confidence interval (CI) 0.71-3.69] or 2-year OS (RR 2.64; 95% CI 0.57-12.27), with considerable heterogeneity (I

Indexed as

hepatocellular carcinomameta-analysisneoadjuvant radiotherapyvascular invasion

Identifiers

PMID42100023
PMCPMC13145327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.